18622EGP
- Active ingredient
- enfortumab vedotin-ejfv
- Strength
- 20 mg
- Form
- vial
- Manufacturer
- EGYPTIAN PHARMACEUTICAL TRADING COMPANY
- Route
- injection
Uses
Used for selected patients with advanced or metastatic urothelial carcinoma.
Do not use if
No absolute contraindications are established, except hypersensitivity to the product.
Side effects
May cause fatigue, peripheral neuropathy, rash, hyperglycemia, diarrhea, and decreased appetite.
Warnings
Monitor for severe skin reactions, hyperglycemia, neuropathy, and ocular disorders.
How it works
An antibody-drug conjugate targeting Nectin-4 and delivering a cytotoxic agent to tumor cells.
Storage
Store refrigerated according to manufacturer recommendations.